 |
 |

Differential Cerebral Metabolic Changes With Paroxetine Treatment of Obsessive-Compulsive Disorder vs Major Depression
Sanjaya Saxena, MD;
Arthur L. Brody, MD;
Matthew L. Ho, BS;
Shervin Alborzian, BS;
Karron M. Maidment, RN;
Narineh Zohrabi, BS;
Mai K. Ho, BS;
Sung-Cheng Huang, PhD;
Hsiao-Ming Wu, PhD;
Lewis R. Baxter, Jr, MD
Arch Gen Psychiatry. 2002;59:250-261.
Background Serotonin reuptake inhibitors (SRIs) effectively treat both major depressive
disorder (MDD) and obsessive-compulsive disorder (OCD). We compared and contrasted
the functional neuroanatomical effects of SRIs in OCD and MDD as these 2 disorders
occurred separately and concurrently by measuring pretreatment to posttreatment
cerebral glucose metabolic changes in OCD vs MDD vs concurrent OCD + MDD.
Methods We obtained [18F]fluorodeoxyglucose positron emission tomography
(PET) brain scans on 25 subjects with OCD, 25 with MDD, and 16 with concurrent
OCD + MDD before and after 8 to 12 weeks of treatment with paroxetine hydrochloride.
Controls (n = 16) were scanned 10 to 12 weeks apart without treatment. Treatment
response was defined as a more than 25% decline in OCD symptom severity, a
more than 50% decline in MDD severity, and "much improved" clinical global
impression.
Results Although all patient groups received the same paroxetine dose for the
same duration, regional metabolic changes differed significantly among diagnostic
groups. Subjects with OCD alone showed significant metabolic decreases in
the right caudate nucleus, right ventrolateral prefrontal cortex (VLPFC),
bilateral orbitofrontal cortex, and thalamus that were not seen in any other
group. Both the MDD and concurrent OCD + MDD groups showed metabolic decreases
in the left VLPFC and increases in the right striatum. Treatment response
was associated with a decrease in striatal metabolism in nondepressed OCD
patients but with an increase in striatal activity in patients with OCD +
MDD.
Conclusions Brain metabolic responses to SRIs are both disorder-specific and response-specific.
They vary according to the underlying pathophysiology of the patient and the
degree of symptomatic improvement.
From the Departments of Psychiatry and Biobehavioral Sciences (Drs
Saxena, Brody, and Baxter, Messrs M. L. Ho and Alborzian, and Mss Maidment,
Zohrabi, and M. K. Ho) and Molecular and Medical Pharmacology (Drs Huang,
Wu, and Baxter), School of Medicine, University of California, Los Angeles;
and the Department of Psychiatry and Behavioral Neurobiology, School of Medicine,
University of Alabama, Birmingham (Dr Baxter).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Identifying Functional Neuroimaging Biomarkers of Bipolar Disorder: Toward DSM-V
Phillips and Vieta
Schizophr Bull 2007;33:893-904.
ABSTRACT
| FULL TEXT
Response-Dependent Differences in Regional Cerebral Blood Flow Changes with Citalopram in Treatment of Major Depression
Joe et al.
JNM 2006;47:1319-1325.
ABSTRACT
| FULL TEXT
Metabolic Imaging of Anterior Capsular Stimulation in Refractory Obsessive-Compulsive Disorder: A Key Role for the Subgenual Anterior Cingulate and Ventral Striatum
Van Laere et al.
JNM 2006;47:740-747.
ABSTRACT
| FULL TEXT
Catechol-O-Methyltransferase val158met Genotype Affects Processing of Emotional Stimuli in the Amygdala and Prefrontal Cortex
Smolka et al.
J. Neurosci. 2005;25:836-842.
ABSTRACT
| FULL TEXT
Subtype-Specific Alterations of {gamma}-Aminobutyric Acid and Glutamate in Patients With Major Depression
Sanacora et al.
Arch Gen Psychiatry 2004;61:705-713.
ABSTRACT
| FULL TEXT
Cerebral Glucose Metabolism in Obsessive-Compulsive Hoarding
Saxena et al.
Am. J. Psychiatry 2004;161:1038-1048.
ABSTRACT
| FULL TEXT
Distinct Neural Correlates of Washing, Checking, and Hoarding Symptom Dimensions in Obsessive-compulsive Disorder
Mataix-Cols et al.
Arch Gen Psychiatry 2004;61:564-576.
ABSTRACT
| FULL TEXT
Insulin Resistance, Affective Disorders, and Alzheimer's Disease: Review and Hypothesis
Rasgon and Jarvik
J. Gerontol. A Biol. Sci. Med. Sci. 2004;59:M178-183.
ABSTRACT
| FULL TEXT
Differential Brain Metabolic Predictors of Response to Paroxetine in Obsessive-Compulsive Disorder Versus Major Depression
Saxena et al.
Am. J. Psychiatry 2003;160:522-532.
ABSTRACT
| FULL TEXT
|